Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues

Frontiers in Veterinary Science

Veterinary Science

Gerald E. Duhamel¹  Magdalena M. Marcinczyk¹  Santiago Peralta²  William P. Katt³ 

[1] Department of Biomedical Sciences and New York Animal Health Diagnostic Center, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States;Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States;Department of Molecular Medicine, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States;

关键词: canine acanthomatous ameloblastoma;    oral tumor;    immunohistochemistry;    HRAS;    somatic mutation;    SP174;   

DOI  :  10.3389/fvets.2023.1281022

 received in 2023-08-21, accepted in 2023-10-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

Differentiating canine acanthomatous ameloblastoma (CAA) from oral squamous cell carcinoma (OSCC) based on routine histopathology can be challenging. We have previously shown that more than 95% of CAAs harbor an HRAS p.Q61R somatic mutation, while OSCCs carry either wild-type alleles or other MAPK pathway activating mutations (e.g., HRAS p.Q61L, BRAF p.V595E). Given that HRAS p.Q61R mutations are highly prevalent in CAA, we hypothesized that a RAS Q61R-specific rabbit monoclonal antibody may be a useful tool for confirmation of CAA by immunohistochemical (IHC) staining. In the present study, we assessed IHC staining of archived formalin-fixed and paraffin-embedded biopsy samples with a diagnosis of CAA (n = 23), using a RAS Q61R-specific rabbit monoclonal antibody (SP174) and an automated IHC stainer. Negative control samples consisted of HRAS p.Q61R mutation-negative OSCC tumors with either a known HRAS p.Q61L mutation (n = 1), BRAF p.V595E mutation (n = 4), or wild-type corresponding alleles (n = 3). We found that all 23 CAAs showed diffuse and strong membranous RAS Q61R immunoreactivity (100% sensitivity), while none of the 8 OSCCs showed immunoreactivity (100% specificity). The data supports the use of RAS Q61R-specific rabbit monoclonal antibody for diagnostic IHC confirmation of CAA and ruling out OSCC in dogs.

【 授权许可】

Unknown   
Copyright © 2023 Peralta, Marcinczyk, Katt and Duhamel.